Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma J Flores-Montero, L Sanoja-Flores, B Paiva, N Puig, O García-Sánchez, ... Leukemia 31 (10), 2094-2103, 2017 | 582 | 2017 |
Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma J Flores‐Montero, R de Tute, B Paiva, JJ Perez, S Böttcher, H Wind, ... Cytometry Part B: Clinical Cytometry 90 (1), 61-72, 2016 | 244 | 2016 |
Measurable residual disease by next-generation flow cytometry in multiple myeloma B Paiva, R Martinez-Martinez, R Maldonado, A Sureda, R Garcia-Sanz, ... J. Clin. Oncol., 2020 | 209 | 2020 |
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC) L Sanoja-Flores, J Flores-Montero, JJ Garcés, B Paiva, N Puig, ... Blood cancer journal 8 (12), 117, 2018 | 91 | 2018 |
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy L Sanoja-Flores, J Flores-Montero, N Puig, T Contreras-Sanfeliciano, ... Blood, The Journal of the American Society of Hematology 134 (24), 2218-2222, 2019 | 85 | 2019 |
Utility of CD 54, CD 229, and CD 319 for the identification of plasma cells in patients with clonal plasma cell diseases F Pojero, J Flores‐Montero, L Sanoja, JJ Pérez, N Puig, B Paiva, ... Cytometry Part B: Clinical Cytometry 90 (1), 91-100, 2016 | 71 | 2016 |
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination JJ Garcés, M Simicek, M Vicari, L Brozova, L Burgos, R Bezdekova, ... Leukemia 34 (2), 589-603, 2020 | 48 | 2020 |
Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma JJ Garcés, MT Cedena, N Puig, L Burgos, JJ Perez, L Cordon, ... Journal of Clinical Oncology 40 (27), 3151-3161, 2022 | 47 | 2022 |
Fluorochrome choices for multi-color flow cytometry J Flores-Montero, T Kalina, A Corral-Mateos, L Sanoja-Flores, ... Journal of immunological methods 475, 112618, 2019 | 46 | 2019 |
GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Measurable residual disease by next … B Paiva, N Puig, MT Cedena, L Rosiñol, L Cordón, MB Vidriales, L Burgos, ... J Clin Oncol 38 (8), 784-792, 2020 | 26 | 2020 |
Detection of circulating tumor plasma cells in monoclonal gammopathies: methods, pathogenic role, and clinical implications L Sanoja-Flores, J Flores-Montero, M Pérez-Andrés, N Puig, A Orfao Cancers 12 (6), 1499, 2020 | 23 | 2020 |
Selection and validation of antibody clones against IgG and IgA subclasses in switched memory B-cells and plasma cells E Blanco, M Perez-Andres, L Sanoja-Flores, M Wentink, O Pelak, ... Journal of Immunological Methods 475, 112372, 2019 | 21 | 2019 |
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma N Puig, J Flores-Montero, L Burgos, MT Cedena, L Cordón, JJ Pérez, ... Cancers 13 (19), 4924, 2021 | 13 | 2021 |
Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma D Damasceno, J Almeida, C Teodosio, L Sanoja-Flores, A Mayado, ... Cancers 13 (6), 1454, 2021 | 13 | 2021 |
Next generation flow (NGF): A high sensitive technique to detect circulating peripheral blood (PB) clonal plasma cells (cPC) in patients with newly diagnosed of plasma cell … L Sanoja-Flores, B Paiva, JA Flores-Montero, N Puig, L Burgos, O García, ... Blood, The Journal of the American Society of Hematology 126 (23), 4180-4180, 2015 | 10 | 2015 |
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies CB García-Calderón, B Sierro-Martínez, E García-Guerrero, ... Frontiers in Immunology 14, 1152498, 2023 | 9 | 2023 |
B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients R Mendonça de Pontes, J Flores-Montero, L Sanoja-Flores, N Puig, ... Cancers 13 (7), 1704, 2021 | 8 | 2021 |
Plasma cell disorders J Flores-Montero, L Sanoja, JJ Pérez, F Pojero, N Puig, MB Vidriales, ... Manual of Molecular and Clinical Laboratory Immunology, 235-250, 2016 | 4 | 2016 |
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma. Cancers. 2021; 13 N Puig, J Flores-Montero, L Burgos, MT Cedena, L Cordon, JJ Perez, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 3 | 2021 |
Non-invasive genetic profiling is highly applicable in multiple myeloma (MM) through characterization of circulating tumor cells (CTCs) L Burgos, D Alignani, JJ Garces, L Ortiz, T Jelinek, V Segura, L Sanoja, ... Blood 128 (22), 801, 2016 | 3 | 2016 |